Camitta B M, Pullen J, Murphy S
Department of Pediatrics, Medical College of Wisconsin, Children's Hospital of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, USA.
Semin Oncol. 1997 Feb;24(1):83-91.
Biological factors and therapy interact in complex ways to affect prognosis of children with acute lymphocytic leukemia. Therefore, it is important that trials prospectively collect data on potential prognostic factors (such as age, white blood cell count, DNA index, cytogenetics, immunophenotype, central nervous system status, and early treatment response) in all patients. As results of treatment improve, subsequent trials must be large enough to detect small differences in outcomes. Results should be reported after sufficient follow-up, using multivariate analyses, and in a format that permits comparison with outcomes at other centers. Attention to the above will permit an approach to treatment that adapts the intensity of therapy to the risk of relapse.
生物因素与治疗以复杂的方式相互作用，从而影响急性淋巴细胞白血病患儿的预后。因此，重要的是，试验要前瞻性地收集所有患者潜在预后因素（如年龄、白细胞计数、DNA指数、细胞遗传学、免疫表型、中枢神经系统状态和早期治疗反应）的数据。随着治疗效果的改善，后续试验必须足够大，以检测结果中的微小差异。应在充分随访后报告结果，采用多变量分析，并以允许与其他中心的结果进行比较的格式呈现。关注上述内容将有助于采取一种根据复发风险调整治疗强度的治疗方法。
